GlassScriptPhysician profile
Elizabeth Rook
NPI 1881878759
$2,519.16
in general payments reported to CMS, 2019-2025
18 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $348 · 2021: $178 · 2022: $51.35 · 2023: $459 · 2024: $563 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,240.72 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.74 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $320.77 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $210.24 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $170.86 | 2019-2020 | |
| Glaxosmithkline, LLC. | $170.37 | 2019-2020 | |
| Celgene Corporation | $139.90 | 2019 | |
| Aurinia Pharma U.S., INC. | $123.23 | 2021 | |
| Amgen INC. | $108.55 | 2020-2024 | Enbrel, Otezla, Tavneos |
| Pfizer INC. | $105.83 | 2019-2024 | |
| Horizon Therapeutics Plc | $80.44 | 2019-2021 | |
| Genentech USA, INC. | $70.69 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $68.38 | 2023-2024 | Saphnelo |
| Lilly USA, LLC | $68.18 | 2019-2024 | Taltz |
| Janssen Biotech, INC. | $52.15 | 2020-2022 | |
| Boston Scientific Corporation | $42.85 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27.89 | 2025 | Eohilia |
| Regeneron Healthcare Solutions, INC. | $19.36 | 2019 | |
| Genzyme Corporation | $15.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Rook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.